The log-rank test revealed that both USP22 and AP4 were positively related to poor overall survival (OS) in CRC patients (USP22: negative 69.63 ± 3.19 months vs. positive 39.37 ± 3.28 months, p < 0.001; AP4: negative 66.27 ± 3.04 months vs. positive 37.37 ± 3.75 months, p < 0.001; respectively; Figure 6E–6F). The gene discussed is USP22; the disease is colorectal carcinoma.